Leo Lens uses its proprietary technology to develop contact lenses that provide sustained drug delivery of medications for ocular disease using the power of digital printing on existing FDA-approved contact lenses.
This method for treating glaucoma, other eye disease and allergies offers non-invasive, cost effective treatment through improved bioavailability, better patient compliance and reduced side effects. Our innovative solutions for using cutting edge technology, mitigates regulatory risks, works seamlessly with existing manufacturing processes and offers doctors the flexibility of prescribing more than one drug for delivery. The value added benefits across supply chain of manufacturer, doctor and patients would make it a first choice treatment.
Global Glaucoma Market = 70 Million Patients
Over 50 years of research and still no commercial solution for treatment via contact lenses.
Lenses showed sustained release of more than 7 days during in vivo studies.
Concept level clinical evaluation with patients is the next step.
In-vivo sustained release for 7 days
In-vitro sustained release for 10 days
Allergy & Comfort Enhancement
In-vitro sustained release from the same lens for 7 days
Low cost/simple to use
Reduced side effects
Low risk, non-invasive treatment
Better patient outcome
Predictable treatment plan
Fewer complications due to reduced side effects
Reduced cost of medical treatment / Reduced hospitalization
Low cost / high-quality products
Low capital investment
Reduced regulatory complexities
First in the market
Pipeline for multiple products
|Low cost / simple to use||Low risk, non-invasive treatment||Low cost / high quality products|
|Higher bioavailability||Better patient outcome||Low capital investment|
|Better compliance||Predictable treatment plan||Reduced regulatory complexities|
|Reduced side effects||Fewer complications due to reduced side effects||Patent protection|
|Comprehensive solution||Customized prescription||First in the market|
|Non-invasive||Reduced cost for medical treatment / Reduced hospitalization||Pipeline for multiple products|
|Factor||Rationale||Eye Drops||Injection/ Implants||LTT Contact Lens|
|High Bioavailability||Sustained delivery. Avoid fluctuations in IOP||✗||✓||✓|
|Low Risk of Side Effects||Avoids giving patient dry eye, infection||✗||✗||✓|
|High Level of Patient Compliance||Better patient outcomes from improved compliance||✗||✓||✓|
|Low-Cost||Manufacturers require acceptable gross margins to participate in this space||✓||✗||✓|
|Easy to Insert and Remove||Non-invasive treatment safe and low-cost Change in medical conditions, requires change in treatment||✓||✗||✓|
|Delivers Multiple Drugs||Customized treatment for patients. Provide lens comfort and treat multiple diseases simultaneously||✗||✗||✓|